0.27
+0.0219(+8.93%)
Currency In USD
| Previous Close | 0.25 |
| Open | 0.25 |
| Day High | 0.27 |
| Day Low | 0.25 |
| 52-Week High | 1.73 |
| 52-Week Low | 0.22 |
| Volume | 1.06M |
| Average Volume | 989,530 |
| Market Cap | 4,775 |
| PE | -0.1 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.54 |
| Moving Average 200 Days | 0.97 |
| Change | 0.02 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $0.86 as of December 25, 2025 at a share price of $0.267. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $7.18 as of December 25, 2025 at a share price of $0.267.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
GlobeNewswire Inc.
Dec 23, 2025 1:30 PM GMT
Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling WorkTAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug
Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
GlobeNewswire Inc.
Dec 16, 2025 2:29 PM GMT
New cash portion of offering includes >20% participation from Directors, Officers and Executive ManagementTAMPA, Fla. and LONDON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology co
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
GlobeNewswire Inc.
Dec 09, 2025 1:40 PM GMT
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates The K-Ras G12V mutation is the oncog